Medical Technology

Venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a leading cause of morbidity and mortality worldwide.

Current standards of care have significant limitations:

In hospitals and private practices, patient photos are essential for documentation, diagnosis, and outcomes tracking — yet most providers still use unsecured smartphone cameras and inconsistent processes.

This leads to HIPAA violations, lost or misfileed images, and inconsistent before-and-after documentation that diminishes clinical and marketing value.

Cervu is developing an innovative at-home pelvic health trainer system that combines a hardware device that features multiple functionalities with a mobile app to deliver personalized care for women seeking to improve their pelvic health.

DermiSense is a medical technology company revolutionizing diagnostic testing by offering a painless alternative to invasive blood draws.

Traditional blood sampling is expensive, resource-intensive, requires specialized training, and often causes patient anxiety—limiting frequent and decentralized testing.

Tricuspid regurgitation (TR) is the most common valvular heart disease, affecting more than 20 million people in the US, including 1.8 million with severe dysfunction.

TR occurs when the tricuspid valve fails to close properly, allowing blood to flow backward from the right ventricle to the right atrium. As severity increases, the heart works harder, leading to reduced quality of life, end-organ dysfunction, and higher mortality.

Imagine Devices Inc. is revolutionizing neonatal and pediatric critical care with a safer, smarter approach to monitoring premature infants.

Each year, over 13 million premature infants are admitted to Neonatal Intensive Care Units (NICUs) worldwide, connected to more than 20 wires, tubes, and sensors for feeding, respiratory support, and vital signs. Conventional systems create serious risks—including nasal and skin injuries, infections, respiratory complications, and high clinical workload.

The $700 billion natural products market—spanning pharmaceuticals, agriculture/animal health, and consumer health—faces severe production bottlenecks. Many of nature’s most valuable metabolites are produced in trace amounts, blocking clinical trials and cost-effective manufacturing.

Traditional strain improvement is slow and incremental. Even CRISPR delivers only modest gains in genetically intractable microbes.

Neurodiverse Technologies develops adaptive, simulation-based tools that bridge the gap between therapy, education, and independence for neurodivergent individuals. Our mission is to create inclusive technologies that empower users to build confidence and readiness for real-world milestones—whether learning to drive, interviewing for a job, or transitioning into independent living.